New Zealand’s medicinal cannabis industry has a much better chance of long-term success than Australia’s thanks to its more user-friendly regulatory environment.
Helius Therapeutics chief commercial officer Julie Curphey said while Australia may be ahead when it comes to production and uptake, New Zealand’s scheme gives doctors and patients a key advantage.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and
international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
I beg to differ, the lack of infrastructure hampers NZ significantly, testing, remediation etc are all offshore, coupled with a tiny market and a lack of health insurance, and tighter interpretations on various aspects of the NZ Scheme, making it stricter than Australia, Germany etc.
While the paperwork in Australia is onerous, it is very streamlined and is compensated by the much lower prices on products.
I suspect this is fluff to leave a paper trail for another capital raise.